Research progress and hotspots of nanoagents for breast cancer based on bibliometric analysis
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · scientometrics and bibliometrics research · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (41)
Show source-provided references
1. Akram M, Iqbal M, Daniyal M et al (2017) Awareness and current knowledge of breast cancer. Biological research 50:1–2310.1186/s40659-017-0140-9 ↗
2. Wang AZ, Langer R, Farokhzad OC (2012) Nanoparticle delivery of cancer drugs. Annu Rev Med 63:185–19810.1146/annurev-med-040210-162544 ↗
3. Pei Z, Chen S, Ding L et al (2022) Current perspectives and trend of nanomedicine in cancer: a review and bibliometric analysis. J Control Release 352:211–24110.1016/j.jconrel.2022.10.023 ↗
4. Yan JD (2014) Status analysis of nanoscience and nanotechnology development by the bibliometrics (in Chinese). Chin Sci Bull (Chin Ver) 59:3637–3644. https://doi.org/10.1360/N972014-0108910.1360/N972014-01089 ↗
5. Agarwal A, Durairajanayagam D, Tatagari S et al (2016) Bibliometrics: tracking research impact by selecting the appropriate metrics. Asian J Androl 18(2):296–309. https://doi.org/10.4103/1008-682X.17158210.4103/1008-682X.171582 ↗
6. Peer D, Karp J, Hong S et al (2007) Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnol 2(12):751–76010.1038/nnano.2007.387 ↗
7. Maulvi FA, Desai DT, Shetty KH et al (2021) Advances and challenges in the nanoparticles-laden contact lenses for ocular drug delivery. Int J Pharm 608:12109010.1016/j.ijpharm.2021.121090 ↗
8. Almeida H, Amaral MH, Lobao P et al (2015) Nanoparticles in ocular drug delivery systems for topical administration: promises and challenges. Curr Pharm Des 21(36):5212–5224. https://doi.org/10.2174/138161282166615092309515510.2174/1381612821666150923095155 ↗
9. Zhou Y, Wang Z, Chen Y et al (2013) Microbubbles from gas-generating perfluorohexane nanoemulsions for targeted temperature-sensitive ultrasonography and synergistic HIFU ablation of tumors. Adv Mater 25(30):4123–413010.1002/adma.201301655 ↗
10. Tang H, Guo Y, Peng L et al (2018) In vivo targeted, responsive, and synergistic cancer nanotheranostics by magnetic resonance imaging-guided synergistic high-intensity focused ultrasound ablation and chemotherapy. ACS Appl Mater Interfaces 10(18):15428–15441.https://doi.org/10.1021/acsami.8b0196710.1021/acsami.8b01967 ↗
11. Shang T, Liu J, Chen Y et al (2018) In vivo targeted cancer theranostics by core/shell‐structured multifunctional prussian blue/PLGA “nanococktails.” Part Part Syst Charact 35(2):1700306. https://doi.org/10.1002/ppsc.20170030610.1002/ppsc.201700306 ↗
12. Pelaz B, Alexiou C, Alvarez-Puebla RA et al (2017) Diverse applications of nanomedicine. ACS Nano 11(3):2313–2381. https://doi.org/10.1021/acsnano.6b0604010.1021/acsnano.6b06040 ↗
13. Li N, Li N, Yi Q et al (2014) Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent. Biomaterials 35(35):9529–9545. https://doi.org/10.1016/j.biomaterials.2014.07.05910.1016/j.biomaterials.2014.07.059 ↗
14. Cai H, Dai X, Wang X et al (2020) A nanostrategy for efficient imaging‐guided antitumor therapy through a stimuli‐responsive branched polymeric prodrug. Adv Sci 7(6):1903243. https://doi.org/10.1002/advs.20190324310.1002/advs.201903243 ↗
15. Li H, Sun J, Zhu H et al (2021) Recent advances in development of dendritic polymer‐based nanomedicines for cancer diagnosis. WIREs Nanomed Nanobiotechnol 13(2):e1670. https://doi.org/10.1002/wnan.167010.1002/wnan.1670 ↗
16. Li Z, Lai X, Fu S et al (2022) Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv Sci 9(22):2201734. https://doi.org/10.1002/advs.20220173410.1002/advs.202201734 ↗
17. Zhang H, Zhu H, Qi T et al (2016) Selective laser melting of high strength Al–Cu–Mg alloys: processing, microstructure and mechanical properties. Mater Sci Eng 656:47–5410.1016/j.msea.2015.12.101 ↗
18. Zhen Y, Zhang H (2019) NLRP3 inflammasome and inflammatory bowel disease. Front Immunol 10:41138710.3389/fimmu.2019.00276 ↗
19. Lu X, Zhang H, Fei G et al (2018) Liquid-crystalline dynamic networks doped with gold nanorods showing enhanced photocontrol of actuation. Adv Mater 30(14):1706597. https://doi.org/10.1002/adma.20170659710.1002/adma.201706597 ↗
20. Wang Dh. (2022) Bibliometrics in library intelligence and scientific and technical intelligence—review of bibliometrics (Second Edition). Leadership Science, (10):153. https://doi.org/10.19572/j.cnki.ldkx.2022.10.05110.19572/j.cnki.ldkx.2022.10.051 ↗
21. Lin YW, Huang CC, Chang HT (2011) Gold nanoparticle probes for the detection of mercury, lead and copper ions. Analyst 136(5):863–871. https://doi.org/10.1039/C0AN00652A10.1039/C0AN00652A ↗
22. Petersen GH, Alzghari SK, Chee W et al (2016) Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J Control Release 232:255–264. https://doi.org/10.1016/j.jconrel.2016.04.02810.1016/j.jconrel.2016.04.028 ↗
23. Zhang Y, Lyu Z, Song F et al (2021) Trends of incidence and mortality of breast cancer worldwide and in China. J Multidiscip Cancer Manag 7(02):14–20
24. Xu Y, Gong M, Wang Y et al (2023) Global trends and forecasts of breast cancer incidence and deaths. Scientific Data 10(1):334. https://doi.org/10.1038/s41597-023-02253-510.1038/s41597-023-02253-5 ↗
25. Zhou W, Kou A, Chen J et al (2018) A retrospective analysis with bibliometric of energy security in 2000–2017. Energy reports 4:724–732. https://doi.org/10.1016/j.egyr.2018.10.01210.1016/j.egyr.2018.10.012 ↗
26. Liu L, Xie N, Guo W, et al. (2015) Progress of research on the application of nanotechnology in breast cancer chemotherapy. Carcinog Teratog Mutagen, 27(1). https://doi.org/10.3969/j.issn.1004-616x.2015.01.01710.3969/j.issn.1004-616x.2015.01.017 ↗
27. Chen Y, Tan C, Zhang H et al (2015) Two-dimensional graphene analogues for biomedical applications. Chem Soc Rev 44(9):2681–2701.https://doi.org/10.1039/C4CS00300D10.1039/C4CS00300D ↗
28. Chen Y, Chen H, Shi J (2013) In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv Mater 25(23):3144–3176. https://doi.org/10.1002/adma.20120529210.1002/adma.201205292 ↗
29. Chen Y, Ye D, Wu M (2014) Break‐up of Two‐Dimensional MnO 2 Nanosheets Promotes Ultrasensitive pH‐Triggered Theranostics of Cancer. Adv Mater 26(41):7019–7026. https://doi.org/10.1002/adma.20140257210.1002/adma.201402572 ↗
30. Chen Y, Meng Q, Wu M et al (2014) Hollow mesoporous organosilica nanoparticles: a generic intelligent framework-hybridization approach for biomedicine. J Am Chem Soc 136(46):16326–16334. https://doi.org/10.1021/ja508721y10.1021/ja508721y ↗
31. Chen Y, Chen HR, Shi JL (2014) Construction of homogenous/heterogeneous hollow mesoporous silica nanostructures by silica-etching chemistry: principles, synthesis, and applications. Acc Chem Res 47(1):125–137. https://doi.org/10.1021/ar400091e10.1021/ar400091e ↗
32. Ferrari M (2010) Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol 28(4):181–188. https://doi.org/10.1016/j.tibtech.2009.12.00710.1016/j.tibtech.2009.12.007 ↗
33. Ferrari M (2008) Beyond drug delivery. Nat Nanotechnol 3(3):131–13210.1038/nnano.2008.46 ↗
34. Bakrania AK, Variya BC, Patel SS (2016) Novel targets for paclitaxel nano formulations: hopes and hypes in triple negative breast cancer. Pharmacol Res 111:577–591. https://doi.org/10.1016/j.phrs.2016.07.02310.1016/j.phrs.2016.07.023 ↗
35. Wan X, Beaudoin JJ, Vinod N et al (2019) Co-delivery of paclitaxel and cisplatin in poly (2-oxazoline) polymeric micelles: implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments. Biomaterials 192:1–14. https://doi.org/10.1016/j.biomaterials.2018.10.03210.1016/j.biomaterials.2018.10.032 ↗
36. Group, Breast Cancer, et al (2023) Chinese expert consensus of albumin-bound paclitaxel in the treatment of breast cancer. Zhonghua zhong liu za zhi [Chinese journal of oncology] 4(3):203–211
37. Wang Y, Liu X (2023) Safety signals of albumin-bound paclitaxel: data mining of the Food and Drug Administration adverse event reporting system. Indian J Pharmacol 55(3):167–173. https://doi.org/10.4103/ijp.ijp_640_2210.4103/ijp.ijp_640_22 ↗
38. Lemenager M, Lecomte S, Bonneterre ME et al (1997) Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur J Cancer 33(2):297–300. https://doi.org/10.1016/S0959-8049(96)00374-710.1016/S0959-8049(96)00374-7 ↗
39. Gao Q, Feng J, Liu W et al (2022) Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment. Adv Drug Deliv Rev 188:114445. https://doi.org/10.1016/j.addr.2022.11444510.1016/j.addr.2022.114445 ↗
40. Yun WS, Kim J, Lim DK et al (2023) Recent studies and progress in the intratumoral administration of nano-sized drug delivery systems. Nanomaterials 13(15):2225. https://doi.org/10.3390/nano1315222510.3390/nano13152225 ↗
41. Ghosh S, Javia A, Shetty S et al (2021) Triple negative breast cancer and non-small cell lung cancer: clinical challenges and nano-formulation approaches. J Control Release 337:27–58. https://doi.org/10.1016/j.jconrel.2021.07.01410.1016/j.jconrel.2021.07.014 ↗